Met Life Investment Management, LLC Astria Therapeutics, Inc. Transaction History
Met Life Investment Management, LLC
- $20.1 Billion
- Q3 2025
A detailed history of Met Life Investment Management, LLC transactions in Astria Therapeutics, Inc. stock. As of the latest transaction made, Met Life Investment Management, LLC holds 18,366 shares of ATXS stock, worth $230,860. This represents 0.0% of its overall portfolio holdings.
Number of Shares
18,366
Previous 24,953
26.4%
Holding current value
$230,860
Previous $133,000
0.75%
% of portfolio
0.0%
Previous 0.0%
Shares
8 transactions
Others Institutions Holding ATXS
# of Institutions
121Shares Held
50.8MCall Options Held
48.8KPut Options Held
55.8K-
Perceptive Advisors LLC New York, NY6.49MShares$81.5 Million0.1% of portfolio
-
Vestal Point Capital, LP New York, NY4.96MShares$62.3 Million1.63% of portfolio
-
Fcpm Iii Services B.V. Naarden, P74.11MShares$51.6 Million5.98% of portfolio
-
Fairmount Funds Management LLC Philadelphia, PA3.55MShares$44.7 Million5.59% of portfolio
-
Black Rock Inc. New York, NY3.52MShares$44.2 Million0.0% of portfolio
About Astria Therapeutics, Inc.
- Ticker ATXS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 15,178,000
- Market Cap $191M
- Description
- Astria Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare and niche allergic, and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in preclinical development stage...